BML-210 Catalog No.:M12478-10 Smiles: CC(C)N1C=C(C2=CC=NC(NC[C@H](C)NC(=O)OC)=N2)C(=N1)C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F

Smiles: CC(C)N1C=C(C2=CC=NC(NC[C@H](C)NC(=O)OC)=N2)C(=N1)C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F

Formula: C29H27F5N2O6S

OVCAR-3= 0

MK-8776 S-isomer suppresses accumulation of the Chk1 pS296 autophosphorylation in a dose-dependent manner

BML-210 Catalog No.:M12478-10 Smiles: CC(C)N1C=C(C2=CC=NC(NC[C@H](C)NC(=O)OC)=N2)C(=N1)C1=CC(Cl)=CC(NS(C)(=O)=O)=C1FBML 210 is a novel HDAC inhibitor, and its mechanism of action has not been characterized. IC50 value: 5 M Target: HDAC4 In vitro: Cell cycle analysis indicated that HeLa cell treatment with 20 and 30 M concentration of BML 210 increased the proportion of cells in G0 G1 phase, and caused accumulation in subG1, indicating that the cells are undergoing apoptosis. BML 210 inhibits the growth of NB4 cells in dose and time dependent manner. Product